Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.83 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.63 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.56 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.56 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.56 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | GNE | Q9Y223 | 1/20 | 0.56 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.54 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.53 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31305639 | 1.00 | L3MBTL1 (0.83) | L3MBTL1EPHX2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL18228118 | 0.98 | L3MBTL1 (0.86) | L3MBTL1EPHX2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL3390298 | 0.98 | L3MBTL1 (0.86) | L3MBTL1EPHX2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL22972207 | 0.95 | L3MBTL1 (0.86) | L3MBTL1EPHX2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL31677824 | 0.95 | L3MBTL1 (0.86) | L3MBTL1EPHX2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL7955601 | 0.93 | L3MBTL1 (0.89) | L3MBTL1EPHX2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL7943306 | 0.91 | L3MBTL1 (1.00) | L3MBTL1EPHX2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL2677200 | 0.87 | L3MBTL1 (0.78) | L3MBTL1EPHX2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL20070481 | 0.84 | L3MBTL1 (0.73) | L3MBTL1EPHX2CHRNB2CHRNB4CHRNA3 | |
| SCHEMBL21650906 | 0.84 | L3MBTL1 (0.73) | L3MBTL1EPHX2SMN1; SMN2ALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2046782-A2 | IMIDAZOLYLPYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | Astra Zeneca AB (SE) | 2009-04-15 | — | — | EP | claimed |
| WO-2008002244-A2 | IMIDAZOL-PYRIMIDINE DERIVATIVES FOR TREATMENT OF DISEASES RELATED TO GLYCOGEN SYNTHASE KINASE (GSK3) | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | claimed |
| EP-1492784-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | Merck & Co., Inc. (US) | 2005-01-05 | — | — | EP | claimed |
| WO-2003082191-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | claimed |
| US-20250228839-A1 | COMPOSITION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE | COLUCID PHARMACEUTICALS, INC. | 2025-07-17 | — | — | US | disclosed |
| US-12257246-B2 | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl[-benzamide | COLUCID PHARMACEUTICALS, INC. (US) | 2025-03-25 | — | — | US | disclosed |
| CN-118439994-A | Preparation method of 2-pyridine carboxamide compound | 江阴迈康升华医药科技有限公司 | 2024-08-06 | — | — | CN | disclosed |
| US-11858910-B2 | Pyridinylmethylenepiperidine derivatives and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| JP-2023123678-A | COMPOSITIONS AND METHODS RELATED TO PYRIDINOYLPIPERIDINE 5-HT1F AGONISTS | コルシド ファーマシューティカルズ，インコーポレイテッド | 2023-09-05 | — | — | JP | disclosed |
| WO-2023152081-A1 | PROCESS FOR PREPARING PYRIDINOYLPIPERIDINES 5-HT1F AGONISTS AND SALTS THEREOF | INKE, S.A. (ES) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023152081-A1 | PROCESS FOR PREPARING PYRIDINOYLPIPERIDINES 5-HT1F AGONISTS AND SALTS THEREOF | INKE, S.A. (ES) | 2023-08-17 | — | — | WO | disclosed |
| US-20230110003-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | Valo Health, LLC | 2023-04-13 | — | — | US | disclosed |
| US-20050222206-A1 | Pyridinoylpiperidines as 5-ht1f agonists | ELI LILLY AND COMPANY | 2005-10-06 | — | — | US | disclosed |
| US-20050222206-A1 | Pyridinoylpiperidines as 5-ht1f agonists | ELI LILLY AND COMPANY | 2005-10-06 | — | — | US | disclosed |
| CN-1642939-A | As 5-HT1FPyridylpiperidines as agonists | LILLY CO ELI (US) | 2005-07-20 | — | — | CN | disclosed |
| WO-2005061439-A1 | SUBSTITUTED (4-AMINOCYCLOHEXEN-1-YL)PHENYL AND (4-AMINOCYCLOHEXEN-1-YL)PYRIDINYL COMPOUNDS AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2005-07-07 | — | — | WO | disclosed |
| EP-1492786-A1 | PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2005-01-05 | — | — | EP | disclosed |
| EP-1492784-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | Merck & Co., Inc. (US) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003084949-A1 | PYRIDINOYLPIPERIDINES AS 5-HT1F AGONISTS | ELI LILLY AND COMPANY (US) | 2003-10-16 | — | — | WO | disclosed |
| WO-2003082191-A2 | SUBSTITUTED 2,3-DIPHENYL PYRIDINES | MERCK & CO., INC. (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12257246-B2 | Composition of 2,4,6-trifluoro-n-[6-(1-methyl-piperidin-4-carbonyl)-pyridin-2-yl[-benzamide | PDGFRA, SLCO1A2, SLCO2A1 | L3MBTL1 4755/4885EPHX2 2355/4885CHRNB2 399/4885 |
| US-20230110003-A1 | PIPERIDINE DERIVATIVES AND COMPOSITIONS FOR THE INHIBITION OF NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE (NAMPT) | NAMPT, NAPRT, NNMT | L3MBTL1 4177/4885EPHX2 3329/4885CHRNB2 2395/4885 |
| US-11858910-B2 | Pyridinylmethylenepiperidine derivatives and uses thereof | HTR1F, HTR1A, HTR5A | L3MBTL1 4874/4885EPHX2 1480/4885CHRNB2 363/4885 |
| US-20250228839-A1 | COMPOSITION OF 2,4,6-TRIFLUORO-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-BENZAMIDE | PDGFRA, SLCO1A2, SLCO2A1 | L3MBTL1 4776/4885EPHX2 2484/4885CHRNB2 422/4885 |
| US-20050222206-A1 | Pyridinoylpiperidines as 5-ht1f agonists | HTR1F, HTR1A, HTR1E | L3MBTL1 3510/4885EPHX2 1924/4885CHRNB2 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.